Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2014

01.02.2014 | Original Article

Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens

verfasst von: Takaaki Tokito, Hirotsugu Kenmotsu, Reiko Watanabe, Ichiro Ito, Takehito Shukuya, Akira Ono, Yukiko Nakamura, Asuka Tsuya, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi, Yasuhisa Ohde, Haruhiko Kondo, Masahiro Endo, Toru Kameya, Takashi Nakajima, Keita Mori, Nobuyuki Yamamoto

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

It is often difficult to diagnose large cell neuroendocrine carcinomas (LCNEC) of the lung using small biopsy specimens. Some recent studies attempted to diagnose LCNEC using biopsy specimens; in 2011, the International Association for the Study of Lung Cancer pathological panels suggested possible LCNEC as a diagnosis for LCNEC by using biopsy specimens. Here, we compared the chemotherapeutic efficacy in possible LCNEC and LCNEC diagnosed using surgically resected specimens.

Methods

We retrospectively reviewed patients who received platinum-based chemotherapy as first-line chemotherapy at our institution during September 2002–September 2011. Further, we compared the clinical characteristics, chemotherapeutic responses, and survival outcomes of patients diagnosed as having “LCNEC definite” with those diagnosed as having “possible LCNEC.”

Results

We selected 34 patients of whom 10 were diagnosed with LCNEC using surgically resected specimens and 24 patients with possible LCNEC were diagnosed using small biopsy specimens. In both groups, almost all patients were men and were smokers. Small-cell carcinoma-based chemotherapy, such as platinum plus irinotecan or platinum plus etoposide, was used for treating 60 % LCNEC patients (6/10) and 67 % possible LCNEC patients. In the LCNEC and possible LCNEC groups, respectively, the response rate was 70 and 54 % (p = 0.39), median progression-free survival was 2.9 and 4.4 months (p = 0.20), and median survival time was 12.8 and 9.1 months (p = 0.50).

Conclusion

No statistically significant differences were found in chemotherapeutic responses and survival outcomes between the 2 groups, which suggests that chemotherapeutic efficacy is similar in both possible LCNEC and LCNEC.
Literatur
1.
Zurück zum Zitat Travis WD, Brambilla E, Muller-Hermelink HK et al (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon Travis WD, Brambilla E, Muller-Hermelink HK et al (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon
2.
Zurück zum Zitat Iyoda A, Hiroshima K, Toyozaki T et al (2001) Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine. Morphology 91:1992–2000 Iyoda A, Hiroshima K, Toyozaki T et al (2001) Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine. Morphology 91:1992–2000
3.
Zurück zum Zitat Takei H, Asamura H, Maeshima A et al (2002) Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 124:285–292PubMedCrossRef Takei H, Asamura H, Maeshima A et al (2002) Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 124:285–292PubMedCrossRef
4.
Zurück zum Zitat Paci M, Cavazza A, Annessi V et al (2004) Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 77:1163–1167PubMedCrossRef Paci M, Cavazza A, Annessi V et al (2004) Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 77:1163–1167PubMedCrossRef
5.
Zurück zum Zitat Sun L, Sakurai S, Sano T et al (2009) High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma. Pathol Int 59:522–529PubMedCrossRef Sun L, Sakurai S, Sano T et al (2009) High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma. Pathol Int 59:522–529PubMedCrossRef
6.
Zurück zum Zitat Asamura H, Kameya T, Matsuno Y et al (2006) Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24:70–76PubMedCrossRef Asamura H, Kameya T, Matsuno Y et al (2006) Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24:70–76PubMedCrossRef
7.
Zurück zum Zitat Igawa S, Watanabe R, Ito I et al (2010) Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer 68:438–445PubMedCrossRef Igawa S, Watanabe R, Ito I et al (2010) Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer 68:438–445PubMedCrossRef
8.
Zurück zum Zitat Shimada Y, Niho S, Ishii G et al (2011) Clinical features of unresectable high grade lung neuroendocrine carcinoma diagnosed using biopsy specimens. Lung Cancer 75:368–373PubMedCrossRef Shimada Y, Niho S, Ishii G et al (2011) Clinical features of unresectable high grade lung neuroendocrine carcinoma diagnosed using biopsy specimens. Lung Cancer 75:368–373PubMedCrossRef
9.
Zurück zum Zitat Travis WD, Brambilla E, Noguchi M et al (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285PubMedCrossRef Travis WD, Brambilla E, Noguchi M et al (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285PubMedCrossRef
10.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
11.
Zurück zum Zitat Rami-Porta R, Ball D, Crowley J et al (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2:593–602PubMedCrossRef Rami-Porta R, Ball D, Crowley J et al (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2:593–602PubMedCrossRef
12.
Zurück zum Zitat Mazieres J, Daste G, Molinier L et al (2002) Large cell neuroendocrine carcinoma of the lung: pathological study and clinical outcome of 18 resected cases. Lung Cancer 37:287–292PubMedCrossRef Mazieres J, Daste G, Molinier L et al (2002) Large cell neuroendocrine carcinoma of the lung: pathological study and clinical outcome of 18 resected cases. Lung Cancer 37:287–292PubMedCrossRef
13.
Zurück zum Zitat Yamazaki S, Sekine I, Matsuno Y et al (2005) Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 49:217–223PubMedCrossRef Yamazaki S, Sekine I, Matsuno Y et al (2005) Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 49:217–223PubMedCrossRef
14.
Zurück zum Zitat Fujiwara Y, Sekine I, Tsuta K et al (2007) Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol 37:482–486PubMedCrossRef Fujiwara Y, Sekine I, Tsuta K et al (2007) Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol 37:482–486PubMedCrossRef
15.
Zurück zum Zitat Rossi G, Cavazza A, Marchioni A et al (2005) Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 23:8774–8785PubMedCrossRef Rossi G, Cavazza A, Marchioni A et al (2005) Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 23:8774–8785PubMedCrossRef
Metadaten
Titel
Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens
verfasst von
Takaaki Tokito
Hirotsugu Kenmotsu
Reiko Watanabe
Ichiro Ito
Takehito Shukuya
Akira Ono
Yukiko Nakamura
Asuka Tsuya
Tateaki Naito
Haruyasu Murakami
Toshiaki Takahashi
Yasuhisa Ohde
Haruhiko Kondo
Masahiro Endo
Toru Kameya
Takashi Nakajima
Keita Mori
Nobuyuki Yamamoto
Publikationsdatum
01.02.2014
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2014
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-012-0509-2

Weitere Artikel der Ausgabe 1/2014

International Journal of Clinical Oncology 1/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.